Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

4.97
-0.0235-0.47%
Volume:21.51K
Turnover:108.19K
Market Cap:31.01M
PE:-0.68
High:5.11
Open:5.00
Low:4.93
Close:4.99
52wk High:13.69
52wk Low:3.98
Shares:6.24M
Float Shares:3.70M
Volume Ratio:1.00
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.3016
EPS(LYR):-2.4500
ROE:-113.59%
ROA:-49.12%
PB:0.97
PE(LYR):-2.03

Loading ...

Aligos Therapeutics - Topline Safety and Efficacy Data Expected in Late Q3 2027

THOMSON REUTERS
·
Jul 13

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

GlobeNewswire
·
Jul 13

Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones
·
Jul 07

Aligos Rises on Receiving Upfront Payment from Hepatitis B Drug License Deal

Reuters
·
Jul 07

Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal

TIPRANKS
·
Jul 07

Aligos Therapeutics Receives USD 25 Million Upfront in Greater China Pevifoscorvir License Deal with Amoytop

Reuters
·
Jul 07

Aligos Therapeutics - Eligible for up to $420 Mln in Milestones and Tiered Royalties

THOMSON REUTERS
·
Jul 07

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

THOMSON REUTERS
·
Jul 07

Aligos Therapeutics Shareholders Approve Directors and Governance Changes

TIPRANKS
·
Jun 27

Aligos Therapeutics Shareholders Approve ESPP Share Reserve Increase, Remove Evergreen Provision

Reuters
·
Jun 27

Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Simply Wall St.
·
Jun 06

Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)

TIPRANKS
·
Jun 01

Aligos Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
May 29

Analysts’ Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)

TIPRANKS
·
May 28

Aligos Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
May 28

Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target

MT Newswires Live
·
May 28

Aligos Therapeutics presents data at EASL congress

TIPRANKS
·
May 27

Aligos says Phase 1 follow-up data for pevifoscorvir sodium suggest reduction in HBV cccDNA reservoir

Reuters
·
May 27

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

GlobeNewswire
·
May 27

H.C. Wainwright Remains a Buy on Aligos Therapeutics (ALGS)

TIPRANKS
·
May 22